Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Nvidia Develops New Location-Verification Technology for AI Chips 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Japan Weighs New Tax Breaks to Boost Corporate Investment Amid Spending Debate 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
US Signals Openness to New Trade Deal as Brazil Shows Willingness, Says USTR Greer 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
